Antimicrobial Susceptibility Patterns and Antimicrobial Therapy of Infections Caused by Species.

: species have become significant sources of infections acquired in hospital settings and are commonly linked to high mortality rates. Antimicrobial resistance can be influenced by species, geographical location, antimicrobial susceptibility testing methods, and the time of bacterial isolation. There are distinct antimicrobial susceptibility patterns among species, and the investigation into potential antibiotic susceptibility variations among species is beneficial. There is no guidance on the treatment of species infections in the literature. Consequently, the purpose of this review was to elaborate on the antimicrobial susceptibility patterns of species through a scoping review of existing studies on the antibiograms of the species and on the illness caused by species. : A comprehensive literature search in PubMed and Web of Science between 1 January 2000 and 30 April 2024 identified all studies, including those that examined antimicrobial susceptibility patterns and antimicrobial therapy of infections caused by species. I considered studies on antimicrobial susceptibility testing for species in which only broth microdilution methods and agar dilution methods were used. : The sensitivity levels of to piperacillin-tazobactam (5-100%), ciprofloxacin (0-43.4%), levofloxacin (30-81.8%), trimethoprim-sulfamethoxazole (0-100%), tigecycline (15-100%), minocycline (60-100%), and rifampicin (94-100%) varied. The sensitivity levels of to piperacillin-tazobactam (3.3-93.3%), ciprofloxacin (1-75%), levofloxacin (12-100%), trimethoprim-sulfamethoxazole (1.02-96.7%), tigecycline (0-52.2%), minocycline (97.5-100%), and rifampicin (20.5-96%) varied. The sensitivity levels of to piperacillin-tazobactam (41.6-94.0%), ciprofloxacin (14-75%), levofloxacin (77.0-100%), trimethoprim-sulfamethoxazole (18.0-100%), tigecycline (50%), minocycline (100%), and rifampicin (66-85.7%) varied. : The majority of the isolates of species were susceptible to minocycline and rifampin. This issue requires professional knowledge integration and treatment recommendations.